Oncology/Hematology

Lung Cancer

More in Lung Cancer

AI Model Has Promise for Predicting Checkpoint Inhibitor Activity in NSCLC

Score based on pathology images an independent predictor of PFS, OS

Dec 27, 2024
A close-up photo of a pathology slide under a microscope.
Metastatic Cancer 'Thrivers'; Celebrity Cancer Diagnoses; 'Would He Have Lived?'

News, features, and commentary about cancer-related issues

Dec 27, 2024
Onco Break over a computer rendering of a cancer cell.
No Seed Oil-Colon Cancer Link; Avoiding Prostate Biopsy; Top Cancer Advances

News, features, and commentary about cancer-related issues

Dec 20, 2024
Onco Break over a computer rendering of a cancer cell.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

Newest EGFR TKIs have changed the game for treating asymptomatic brain metastases

Dec 20, 2024
A computer rendering of a transparent head with brain metastases highlighted.
New First-Line Option for Advanced ALK-Positive Lung Cancer

In randomized study, ensartinib doubled PFS versus first-generation ALK inhibitor

Dec 18, 2024
FDA APPROVED ensartinib (Ensacove) over a computer rendering of lung cancer.
Hair Growth After Cancer; 'Global' Early-Onset CRC; Retifanlimab Boosts OS in NSCLC

News, features, and commentary about cancer-related issues

Dec 13, 2024
Onco Break over a computer rendering of a cancer cell.
Lung Cancer Drug Osimertinib Tied to Cardiac Events, Even in Low-Risk Patients

Signal largely driven by newly emerging arrhythmias

Dec 12, 2024
A computer rendering of a heart and pulse.
Industry Clinic • Ad Insights
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients

Dec 12, 2024
A photo of a male physician showing his male patient a tablet.
Industry Clinic • Ad Insights
Alecensa (alectinib) Offers Hope for Certain Patients With ALK Positive NSCLC

Dec 10, 2024
A photo of a female physician at her desk talking to her male patient.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns

News, features, and commentary about cancer-related issues

Dec 05, 2024
Onco Break over a computer rendering of a cancer cell.
Nearly 6 Million Deaths From Five Major Cancer Types Averted Since 1975

Prevention and screening efforts accounted for 80% of those averted deaths

Dec 05, 2024
A photo of a stethoscope in the center of a circle of variously colored cancer ribbons.
Durvalumab Wins FDA Approval in Limited-Stage SCLC

Unprecedented 22.5-month improvement in median overall survival as consolidation therapy

Dec 05, 2024
FDA APPROVED durvalumab (Imfinzi) over a computer rendering of lung cancer.
FDA OKs First Drug Targeting NRG1 Gene Fusion in Pancreatic, Lung Cancers

Zenocutuzumab achieved response rates of 40% in pancreatic adenocarcinoma, 33% in advanced NSCLC

Dec 04, 2024
FDA APPROVED zenocutuzumab-zbco (Bizengri) over a computer rendering of monoclonal antibodies attacking cancer cells.
Industry Clinic • Ad Insights
What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?

Dec 04, 2024
A computer rendering of a transparent body with a tumor in the lungs highlighted.
More in Lung Cancer

Continuing Medical Education

1.00 CME Credits
Critical Clues: Identifying and Managing Interstitial Lung Disease in Patients With Breast Cancer

1.00 CME Credits
Precision in Progress: Targeting the Future of Upper GI Cancers

0.50 CME Credits
Melanoma: Expert Recommended Approaches to Selection and Sequencing of Immunotherapies

0.75 CME Credits
Ask the Experts: Latest Advances in Treatment of Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer

1.00 CME Credits
Expert Strategies to Optimize the Integration of CAR T-Cell Therapy Into Earlier Lines of Multiple Myeloma Treatment

1.00 CME Credits
Fostering Equity in Cancer Care: Culturally Competent Approaches for LGBTQ+ Patients

1.00 CME Credits
Optimizing Adherence, Tolerability, and Persistence to Oral CLL Therapies

1.00 CME Credits
Improving Outcomes in mUC Through Real-World Insights and Expert-Led, Team-Based Planning